Cited by 674Transcranial Magnetic Stimulation StudiesTreatment of Major DepressionElectroconvulsive Therapy Studies

The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder

Open access
Perera, Tarique, George, Mark S., Grammer, Geoffrey, Janicak, Philip G., Pascual-Leone, Alvaro, Wirecki, Theodore S.·2016·Brain Stimulation

Abstract

BACKGROUND: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4-6 weeks (20-30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated in 2013. METHODS: This consensus review was written by cTMSs leaders, informed by membership polls, and approved by the governing board. It summarizes current evidence for the safety and efficacy of the use of TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the published TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength of evidence using the Levels of Evidence framework published by the University of Oxford Centre for Evidence Based Medicine. The authors then summarize essentials for using TMS therapy in routine clinical practice settings derived from discussions and polls of cTMSs members. Finally, each summary clinical recommendation is presented with the substantiating peer-reviewed, published evidence supporting that recommendation. When the current published clinical trial evidence was insufficient or incomplete, expert opinion was included when sufficient consensus was available from experienced clinician users among the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015. CONCLUSIONS: Daily left prefrontal TMS has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant. Following the clinical recommendations in this document should result in continued safe and effective use of this exciting new treatment modality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.brs.2016.03.010

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [29]Howick J Chalmers I Glasziou P Greenhaigh C Liberatir A Moschetti I The 2011 Oxford CEBM levels of evidence (introductory document) Oxford Centre for Evidence Based Medicine Oxford 2011

Cited by

Sorted by citations

Authors
Perera, T., George, M. S., Grammer, G., Janicak, P. G., Pascual-Leone, A., & Wirecki, T. S.
Affiliations
  • Medical University of South Carolina (US)
  • Northwestern University (US)
Corresponding author
George, Mark S.
Venue
Brain Stimulation
Publisher
Elsevier BV
Published
2016-05
Volume
9
Issue
3
Pages
336-346
ISSN
  • 1876-4754 (ISSN-L)
  • 1935-861X
OpenAlex
W2302097048
Cited by
674
References
73
Citations by year
2026: 48 · 2025: 79 · 2024: 72 · 2023: 72 · 2022: 74 · 2021: 91 · 2020: 68 · 2019: 91 · 2018: 41 · 2017: 28 · 2016: 9
FWCI
30.86
Type
journal article
Language
en
Open access
Locations
  • Brain stimulation (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • BrainsWay
  • National Institute of Mental Health (R21MH099196)
Topics
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
transcranial magnetic stimulation, major depressive disorder, treatment-resistant depression, antidepressant treatment, left prefrontal cortex, treatment guidelines, treatment efficacy and safety, level of evidence
MeSH terms
Adult, Antidepressive Agents, Major Depressive Disorder, Humans, Societies, Medical, Treatment Outcome, Prefrontal Cortex, Evidence-Based Medicine, Transcranial Magnetic Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review